Upsher-Smith Laboratories introduces new formulation of PreNexa Rx prenatal vitamins

Upsher-Smith Laboratories, Inc. is pleased to announce the introduction of a new formulation of PreNexa® Rx prenatal vitamins.  The new formulation contains an increased amount of algal-oil, plant-based docosahexaenoic acid (DHA), from 265 mg to 300 mg and increased vitamin D3, from 170 IU to 400 IU.

DHA, a key omega-3 fatty acid used throughout the body, helps support fetal and infant brain and eye development. Vitamin D is an essential vitamin for mom's and baby's skeletal health.

"PreNexa® is the fastest growing single-capsule prenatal vitamin with plant-based DHA on the market.  This new formulation reflects the increasing body of evidence pointing to the important role DHA and vitamin D play in pregnancy, lactation and infancy," said Wesley Mark Todd, MD, Senior Director Medical Affairs, Upsher-Smith Laboratories, Inc.  

The NDC number for the new formulation of PreNexa® is 0245-0177-30.  Key product features remain the same, including: the bottle configuration, amount per bottle (30 gel capsules), look of the gel capsule, and regimen of one pill once daily.  

SOURCE Upsher-Smith Laboratories, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Epigenomic dynamics shape human brain development and neuropsychiatric disorder risks